Aciclovir, valaciclovir: risk of acute generalised exanthematous pustulosis
- PDF / 169,537 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 90 Downloads / 145 Views
1
Aciclovir, valaciclovir: risk of acute generalised exanthematous pustulosis A signal for aciclovir- and valaciclovir-related acute generalised exanthematous pustulosis (AGEP) has been reported by the Uppsala Monitoring Centre in the WHO Pharmaceuticals Newsletter. An association between aciclovir and AGEP was identified in December 2018 in routine signal detection screening of VigiBase, the WHO global databse of individual case safety reports. Valciclovir was subsequently added to the assessment. Ten cases of AGEP in patients receiving aciclovir were reported to VigiBase as of October 2019, and fourteen cases in patients receiving valciclovir were reported as of December 2019, from 12 countries throughout the world. However, in many cases in both cases series, co-reported drugs included labelling of AGEP or other severe cutaneous adverse reactions (SCARs) including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). AGEP is not currently included in labelling for aciclovir or valaciclovir. "In these case series, there are several cases where aciclovir and, though to a lesser extent, valaciclovir, can be strongly suspected to have been the cause of AGEP, and in two literature reports, this was confirmed by patch tests. Since the condition canbe confused with a herpes eruption, it seems important to warn that aciclovir could potentially cause the skin reaction," said the author. Westerberg C. Aciclovir or valaciclovir - Acute generalised exanthematous pustulosis WHO Pharmaceuticals Newsletter : 11-17, No. 4, Sep 2020. Available from: URL: 803502315 https://www.who.int/publications/i/item/9789240010741
0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 19 Sep 2020 No. 1822
Data Loading...
